CymaBay Therapeutics (CBAY) has released an update to notify the public and investors about its officers.
CymaBay Therapeutics, Inc. amended its Non-Employee Director Compensation Program on January 24, 2024, increasing the annual equity award for directors to approximately $250,000 and for newly hired directors to about $400,000. The revised program took effect on January 1, 2024. Additionally, on the same day, Daniel Menold stepped down as the principal accounting officer, and Harish Shantharam assumed the position, maintaining his roles as the principal financial officer and Chief Financial Officer, with Menold remaining an employee of the company.
For further insights into CBAY corporate activity, check out TipRanks’ Insiders Trading Activity page.
